References
- Cancer Facts and Figures 2016American Cancer Society2016 Cancer.org (online). Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016.htmlAccessed January 23, 2018
- SaenzRTrends in breast cancer mortality in the United StatesPRB (online). Available from: https://www.prb.org/breastcancer/Accessed October 17, 2018
- Estimated Breast Cancer Mortality Worldwide in 2012Globocan2012World Health Organization (Online). Available from: https:/www.uicc.org/sites/main/files/private/GLOBOCAN2012_Cancer_Fact-Sheets_BreastCancer.pdfAccessed October 17, 2018
- Cancer Facts and Figures 2016American Cancer Society2016 Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdfAccessed January 23, 2018
- FisherBCostantinoJPWickerhamDLTamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyJ Natl Cancer Inst200597221652166216288118
- National Cancer Institute2011 webpage on the InternetBreast Cancer Risk Assessment Tool [updated May 16, 2011] Available from: https://www.cancer.gov/bcrisktool/Accessed January 23, 2018
- VogelVGCostantinoJPWickerhamDLNational Surgical Adjuvant Breast and Bowel ProjectUpdate of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancerCancer Prev Res (Phila)20103669670620404000
- CuzickJSestakIForbesJFIBIS-II investigatorsAnastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialLancet201438399221041104824333009
- GossPEIngleJNAlés-MartínezJENCIC CTG MAP.3 Study InvestigatorsExemestane for breast-cancer prevention in postmenopausal womenN Engl J Med2011364252381239121639806
- FreedmanANGraubardBIRaoSRMcCaskill-StevensWBallard-BarbashRGailMHEstimates of the number of US women who could benefit from tamoxifen for breast cancer chemopreventionJ Natl Cancer Inst200395752653212671020
- SmithSGSestakIForsterAFactors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisAnn Oncol201627457559026646754
- WangHLarsonSSnyderCFBreast cancer chemoprevention in primary care: Assessing readiness for changeJ Clin Oncol20163415_suppl1547
- RopkaMEKeimJPhilbrickJTPatient decisions about breast cancer chemoprevention: a systematic review and meta-analysisJ Clin Oncol201028183090309520458026
- USPTF A and B RecommendationsThe Department of Health and Human Services 2015 [updated April 2017] Available from: https://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/Accessed January 23, 2018
- FreedmanANYuBGailMHBenefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or olderJ Clin Oncol201129172327233321537036
- GailMHCostantinoJPBryantJWeighing the risks and benefits of tamoxifen treatment for preventing breast cancerJ Natl Cancer Inst199991211829184610547390
- CapriniJAThrombosis risk assessment as a guide to quality patient careDis Mon2005512–3707815900257
- Barrett-ConnorEMoscaLCollinsPRaloxifene Use for The Heart (RUTH) Trial InvestigatorsEffects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenN Engl J Med2006355212513716837676
- TaylorRTaguchiKTamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lumpAnn Fam Med20053324224715928228
- DemissieSSillimanRALashTLAdjuvant tamoxifen: predictors of use, side effects, and discontinuation in older womenJ Clin Oncol200119232232811208822